One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Publication number: 20150037417Abstract: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.Type: ApplicationFiled: July 15, 2014Publication date: February 5, 2015Applicant: Egalet Ltd.Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Christine Andersen
-
Publication number: 20150037412Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Applicant: PURDUE PHARMA L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20150037413Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Applicant: PURDUE PHARMA L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20150037411Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Applicant: PURDUE PHARMA L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20150038524Abstract: Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.Type: ApplicationFiled: September 29, 2011Publication date: February 5, 2015Applicant: ASTRAZENECA INTELLECTUAL PROPERTYInventors: Bengt Leonard Aslund, Carl-Johan Aurell, Martin Hans Bohlin, David Richard Jensen, David Thomas Jonaitis, Eric Thomas Healy, Bo Ingvar Ymén, Stephan Parent, Tesfai Sebhatu
-
Patent number: 8946253Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: April 17, 2013Date of Patent: February 3, 2015Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 8945614Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: GrantFiled: March 5, 2013Date of Patent: February 3, 2015Assignee: Durect CorporationInventors: Su Il Yum, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton, Roger Fu, Michael S. Zamloot
-
Patent number: 8946254Abstract: Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the ?-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.Type: GrantFiled: January 10, 2013Date of Patent: February 3, 2015Assignee: Virginia Commonwealth UniversityInventors: Yan Zhang, Kurt F. Hauser, Dana E. Selley
-
Publication number: 20150030677Abstract: Disclosed is an immediate release solid oral dosage form comprising (i) an active agent; and (ii) a material that is sensitive to acidic pH;Type: ApplicationFiled: March 1, 2013Publication date: January 29, 2015Applicant: Rhodes Pharmaeuticals L.P.Inventors: Akwete L. Adjei, Sibao Chen, Robert J. Kupper, Vincent Mancinelli
-
Publication number: 20150031635Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: ApplicationFiled: June 30, 2014Publication date: January 29, 2015Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
-
Publication number: 20150031718Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.Type: ApplicationFiled: August 27, 2014Publication date: January 29, 2015Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 8940330Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.Type: GrantFiled: September 18, 2012Date of Patent: January 27, 2015Assignee: Orexo ABInventor: Andreas Fischer
-
Patent number: 8940753Abstract: The present invention relates to methods for treating pruritus with anti-pruritic compositions.Type: GrantFiled: August 1, 2014Date of Patent: January 27, 2015Assignee: Trevi Therapeutics, Inc.Inventor: Thomas Sciascia
-
Patent number: 8940729Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.Type: GrantFiled: April 11, 2012Date of Patent: January 27, 2015Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
-
Publication number: 20150025100Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.Type: ApplicationFiled: December 13, 2013Publication date: January 22, 2015Applicant: Progenics Pharmaceuticals, Inc.Inventors: Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
-
Publication number: 20150024058Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.Type: ApplicationFiled: October 1, 2014Publication date: January 22, 2015Inventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
-
Publication number: 20150025101Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: September 18, 2014Publication date: January 22, 2015Inventors: Robert F. KAIKO, Robert D. COLUCCI
-
Publication number: 20150025102Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.Type: ApplicationFiled: September 29, 2014Publication date: January 22, 2015Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
-
Publication number: 20150024048Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.Type: ApplicationFiled: July 29, 2014Publication date: January 22, 2015Inventors: Pernille Hoyrup Hemmingsen, Anders Vagno Pedersen, Daniel Bar-Shalom
-
Patent number: 8936812Abstract: Disclosed is a substantially non-releasable form of an opioid antagonist containing the opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic material(s) such that the antagonist is not released or substantially not released during its transit through the gastrointestinal tract when administered orally in an intact oral dosage form. Oral dosage forms containing an opioid agonist and a substantially non-releasable form of an opioid antagonist are also disclosed.Type: GrantFiled: October 4, 2013Date of Patent: January 20, 2015Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J.David Haddox
-
Publication number: 20150017267Abstract: The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.Type: ApplicationFiled: March 5, 2013Publication date: January 15, 2015Applicant: The Regents of the University of CaliforniaInventors: Alonso G.P. Guedes, Bruce D. Hammock, Christophe Morisseau
-
Publication number: 20150018379Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.Type: ApplicationFiled: May 11, 2012Publication date: January 15, 2015Applicant: Euro-Celtique S.A.Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
-
Publication number: 20150017228Abstract: The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of morphine and a method of synthesising the same. The morphine entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage, the nanodispersion is dried to form a powder.Type: ApplicationFiled: July 21, 2014Publication date: January 15, 2015Applicant: KIMIA ZIST PARSIAN COInventor: Mehrdad Hamidi
-
Publication number: 20150017240Abstract: An oral pharmaceutical composition in unit dosage form comprising: (1) a first portion comprising: an active ingredient and a pH-dependent component, and (2) a second portion comprising a pH-raising agent is provided. Methods of administering the composition are also provided.Type: ApplicationFiled: September 26, 2014Publication date: January 15, 2015Inventors: Manish S. Shah, Ray J. DiFalco
-
Patent number: 8933092Abstract: Methods and compositions for the alleviation of pain in a patient. The methods and compositions sequentially administer a therapeutically effective amount of first compound having opioid receptor agonist activity, followed by a therapeutic effective amount of a second or subsequent compound(s) having opioid receptor agonist activity, one or more non-opioid analgesic compounds or one or more hybrid opioid compounds, or mixtures thereof. The methods and compositions effectively alleviate pain with a lower incidence of opioid-induced side effects.Type: GrantFiled: May 31, 2012Date of Patent: January 13, 2015Assignee: Qrxpharma LimitedInventor: John W. Holaday
-
Publication number: 20150011577Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Publication number: 20150010623Abstract: Controlled release preparations and soft capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release soft capsules, where the fill contains a suspension and/or an emulsion.Type: ApplicationFiled: August 15, 2014Publication date: January 8, 2015Inventors: EmadEldin M. Hassan, Nachiapan Chidambaram, Aqeel A. Fatmi
-
Patent number: 8927716Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: GrantFiled: May 7, 2013Date of Patent: January 6, 2015Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Patent number: 8927011Abstract: A process for advantageously producing tablets having an improved release property and an excellent stability to change with time is provided. The process is for producing tablets containing a morphinan compound represented by the Formula (I) below or pharmaceutically acceptable acid addition salt thereof and an acidic substance such as fumaric acid, maleic acid or adipic acid, and characterized in that the morphinan compound or a pharmaceutically acceptable acid addition salt thereof is granulated by wet granulation together with (an) excipient(s) prior to adding the acidic substance thereto.Type: GrantFiled: May 20, 2008Date of Patent: January 6, 2015Assignee: Toray Industries, Inc.Inventors: Hiroshi Suzuki, Tomohiro Yoshinari
-
Publication number: 20150005336Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: September 18, 2014Publication date: January 1, 2015Inventors: Robert F. KAIKO, Robert D. Colucci
-
Publication number: 20150005335Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.Type: ApplicationFiled: September 17, 2014Publication date: January 1, 2015Inventors: Bianca BRÖGMANN, Silke MÜHLAH, Christof Spitzley
-
Publication number: 20150005334Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.Type: ApplicationFiled: September 12, 2014Publication date: January 1, 2015Inventors: Manish S. SHAH, Ray J. DiFalco, Stefan Aigner
-
Publication number: 20150005332Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: ApplicationFiled: July 1, 2014Publication date: January 1, 2015Inventors: Roman RARIY, Alison FLEMING, Jane C. HIRSH, Said SAIM, Ravi K. VARANASI
-
Publication number: 20150004244Abstract: Tamper-resistance pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: ApplicationFiled: June 30, 2014Publication date: January 1, 2015Inventors: Roman RARIY, Alison Fleming, Jane C. Hirsh, Said SAIM, Ravi K. Varanasi
-
Publication number: 20150005333Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: September 11, 2014Publication date: January 1, 2015Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 8920836Abstract: A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are preferably made by melt extrusion, and can have rubbery characteristics and can exhibit tamper resistance.Type: GrantFiled: February 11, 2005Date of Patent: December 30, 2014Assignee: Euro-Celtique S.A.Inventors: Geoffrey Gerard Hayes, Hassan Mohammad, Harjit Tamber, Malcolm Walden, Steve Whitelock, Helen Kathleen Danagher, Derek Allan Prater
-
Patent number: 8921387Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: June 6, 2011Date of Patent: December 30, 2014Assignee: RB Pharmaceuticals LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 8921556Abstract: The present disclosure provides improved methods for N-dealkylation of tertiary amines, including methods for N-demethylation of alkaloids and opioids, in which the dealkylation reaction is carried out in a solvent comprising a tertiary alcohol. The present disclosure also provides improved processes for preparing semi-synthetic opioids that incorporate the disclosed methods for N-dealkylation of tertiary amines.Type: GrantFiled: December 11, 2012Date of Patent: December 30, 2014Assignee: Rhodes TechnologiesInventors: Joshua Robert Giguere, Helge Alfred Reisch, Sergio Sandoval, Jake Larry Stymiest
-
Patent number: 8921386Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.Type: GrantFiled: May 31, 2012Date of Patent: December 30, 2014Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
-
Patent number: 8921557Abstract: The present invention relates to a novel process for preparing opiates or salts thereof. More particularly, the present invention relates to oxidizing the starting material in a continuous flow reactor, followed by either an isolation of the intermediate, or a direct reduction reaction.Type: GrantFiled: March 21, 2011Date of Patent: December 30, 2014Assignee: Siegfried AGInventors: Beat Weber, Stefan Sahli
-
Publication number: 20140377349Abstract: The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day.Type: ApplicationFiled: June 29, 2012Publication date: December 25, 2014Applicant: DEVELCO PHARMA SCHWEIZ AGInventors: Hélène Rey, Marc Fischer, Mathias Scheer, Dirk Kramer
-
Publication number: 20140377352Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: September 12, 2014Publication date: December 25, 2014Inventors: Manish S. Shah, Ray J. DiFalco
-
Publication number: 20140378498Abstract: The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.Type: ApplicationFiled: September 5, 2014Publication date: December 25, 2014Inventors: KRISHNA DEVARAKONDA, MICHAEL J. GIULIANI, VISHAL K. GUPTA, RALPH A. HEASLEY, SUSAN SHELBY
-
Publication number: 20140378496Abstract: Pharmaceutical combinations of opioid analgesics and analgesics that act through non-opioid mechanisms are commonly used to provide pain relief. An example of this pharmaceutical combination is the product Vicodin™, where the opioid analgesic is hydrocodone and the non-opioid is acetaminophen. However, liver toxicity from the acetaminophen component is common. The invention provides an improvement over the opioid and acetaminophen pharmaceutical combinations for the management of pain by the concomitant administration of an opioid analgesics and the non-opioid analgesic 3-hydroxyacetanilide. This combination has been found to exhibit unexpectedly enhanced analgesic activity when dosed orally in a mammal.Type: ApplicationFiled: November 9, 2012Publication date: December 25, 2014Inventor: Jonathan Wray
-
Publication number: 20140378497Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.Type: ApplicationFiled: September 5, 2014Publication date: December 25, 2014Applicant: Reckitt Benckiser Healthcare (UK) LimitedInventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
-
Publication number: 20140377348Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: ApplicationFiled: September 11, 2014Publication date: December 25, 2014Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Patent number: 8916195Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.Type: GrantFiled: June 4, 2007Date of Patent: December 23, 2014Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
-
Patent number: 8916581Abstract: This invention relates to S-MNTX, methods of producing S-MNTX, pharmaceutical preparations comprising S-MNTX and methods for their use.Type: GrantFiled: June 23, 2011Date of Patent: December 23, 2014Assignee: Progenics Pharmaceuticals, Inc.Inventors: Thomas A. Boyd, Howard Wagoner, Suketu P. Sanghvi, Christopher Verbicky, Stephen Andruski
-
Publication number: 20140370005Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.Type: ApplicationFiled: June 26, 2014Publication date: December 18, 2014Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow
-
Publication number: 20140370006Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.Type: ApplicationFiled: June 26, 2014Publication date: December 18, 2014Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow